| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0a910d33c239980f3a705e312c5bad6a |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4965
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-497
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-663
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-675
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-08 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-497
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-675
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-663 |
| filingDate |
2004-09-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2010-09-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_76ae523fad5fde3592242cd79576c55e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_feffc3ae21fd81f348f283731ef00a47 |
| publicationDate |
2010-09-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
RU-2398588-C2 |
| titleOfInvention |
Combination containing n-(3-methoxy-5-methylpyrazine-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)puridine-3-sulphonamide and lhrh-analogue and/or biphosphonate |
| abstract |
FIELD: medicine, pharmaceutics. n SUBSTANCE: invention refers to medical products and concerns a combination for prostate cancer treatment containing effective amounts of N-(3-methoxy-5-methylpyrazine-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide or its pharmaceutically acceptable salt and pamidronate. There is also disclosed a method of prostate cancer treatment and application of the combination for preparing a medicinal agent used in prostate cancer treatment. n EFFECT: combination under the invention exhibits synergetic effect with respect to inhibiting metastases to bone and soft tissues in prostate cancer treatment. n 4 cl |
| priorityDate |
2003-09-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |